Greenwich LifeSciences reported cash from operations of -$4.70M and free cash flow of -$4.70M for the quarter ended Mar 2026, down 156.3% year over year. This cash flow statement covers 27 quarters of results from Sep 2019 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||
| Net Income | -0.75M | -0.86M | -2.36M | -1.97M | -0.75M | -2.32M | -2.79M | -2.12M | -1.63M | -2.39M | -2.75M | -2.47M | -2.61M | -2.67M | -9.67M | -2.74M | -4.03M | -4.15M | -7.92M | -5.66M | |||||||
| Share-based Compensation | 0.17M | 0.17M | 0.17M | 0.17M | 0.22M | 0.76M | 0.59M | 0.59M | 0.59M | 0.59M | 0.59M | 1.50M | 1.50M | 0.91M | 5.47M | 3.13M | 3.13M | 3.13M | 2.17M | 3.23M | |||||||
| Cash from Operations | -0.60M | -0.89M | -2.26M | -1.95M | -0.53M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.78M | -1.05M | -2.58M | -1.85M | -1.83M | -2.23M | -2.67M | -3.17M | -4.70M | |||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||||
| Amortizatization of Intangibles | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 903.00 | 876.00 | ||||||||||
| Change in Working Capital | |||||||||||||||||||||||||||
| Change in Account Payables | -0.33M | -0.07M | -0.07M | 0.03M | 0.09M | 0.99M | -0.56M | 2.03M | -0.64M | 0.76M | -0.19M | 2.14M | -0.37M | ||||||||||||||
| Change in Accured Expenses | 0.02M | 0.06M | 0.01M | -0.14M | -0.01M | 0.01M | 0.03M | -0.03M | -0.01M | 0.07M | -0.03M | 0.00M | -0.03M | 0.05M | 0.28M | 0.01M | -0.00M | 0.12M | 0.24M | -0.22M | |||||||
| Financing Activities | |||||||||||||||||||||||||||
| Other financing activities | 0.30M | 2.20M | 0.49M | 2.61M | 0.14M | 5.55M | 9.03M | ||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||||
| Long-Term Debt Issuances | 0.12M | -0.55M | 5.51M | 2.02M | |||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 0.91M | 0.91M | 0.89M | 0.91M | 0.89M | 0.89M | 0.89M | 0.89M | 0.89M | 0.89M | |||||||||||||||||
| Net Equity Issued and Repurchased | 0.56M | 0.30M | 0.27M | 1.18M | |||||||||||||||||||||||
| Misc. | |||||||||||||||||||||||||||
| Cash from Financing Activities | 0.56M | -5.51M | -2.02M | 0.30M | 2.77M | 1.18M | 0.12M | 0.49M | 2.61M | 3.35M | 5.55M | 9.03M | |||||||||||||||
| Change in Cash | -0.60M | -0.89M | -1.70M | -7.46M | -2.56M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.48M | 1.72M | -1.40M | -1.73M | -1.34M | 0.38M | 0.68M | 2.37M | 4.33M | |||||||
| Free Cash Flow | -0.60M | -0.89M | -2.26M | -1.95M | -0.53M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.78M | -1.05M | -2.58M | -1.85M | -1.83M | -2.23M | -2.67M | -3.17M | -4.70M | |||||||
| Net Cash Flow | -0.60M | -0.89M | -1.70M | -7.46M | -2.56M | -1.55M | -2.17M | -1.56M | -0.97M | -1.80M | -2.15M | -1.48M | 1.72M | -1.40M | -1.73M | -1.34M | 0.38M | 0.68M | 2.37M | 4.33M |